Selectively targeting disease‐restricted secretogranin III to alleviate choroidal neovascularization
- 17 December 2021
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 36 (1) , e22106
Abstract
Choroidal neovascularization (CNV), a leading cause of blindness in the elderly, is routinely treated with vascular endothelial growth factor (VEGF) inhibitors that have limited efficacy and potentially adverse side effects. An unmet clinical need is to develop novel therapies against other angiogenic factors for alternative or combination treatment to improve efficacy and safety. We recently described secretogranin III (Scg3) as a disease‐selective angiogenic factor, causally linked to diabetic retinopathy and acting independently of the VEGF pathway. An important question is whether such a disease‐selective Scg3 pathway contributes to other states of pathological angiogenesis beyond diabetic retinopathy. By applying a novel in vivo endothelial ligand binding assay, we found that the binding of Scg3 to CNV vessels in live mice was markedly increased over background binding to healthy choriocapillaris and blocked by an Scg3‐neutralizing antibody, whereas VEGF showed no such differential binding. Intravitreal injection of anti‐Scg3 humanized antibody Fab (hFab) inhibited Matrigel‐induced CNV with similar efficacy to the anti‐VEGF drug aflibercept. Importantly, a combination of anti‐Scg3 hFab and aflibercept synergistically alleviated CNV. Homozygous deletion of the Scg3 gene markedly reduced CNV severity and abolished the therapeutic activity of anti‐Scg3 hFab, but not aflibercept, suggesting a role for Scg3 in VEGF‐independent CNV pathogenesis and therapy. Our work demonstrates the stringent disease selectivity of Scg3 binding and positions anti‐Scg3 hFab as a next‐generation disease‐targeted anti‐angiogenic therapy for CNV.Keywords
This publication has 49 references indexed in Scilit:
- Intravital analysis of vascular permeability in mice using two-photon microscopyScientific Reports, 2013
- CCR3 and Choroidal NeovascularizationPLOS ONE, 2011
- A Subretinal Matrigel Rat Choroidal Neovascularization (CNV) Model and Inhibition of CNV and Associated Inflammation and Fibrosis by VEGF TrapInvestigative Ophthalmology & Visual Science, 2010
- Tubby and tubby‐like protein 1 are new MerTK ligands for phagocytosisThe EMBO Journal, 2010
- Vascular Endothelial Growth Factor as an Autocrine Survival Factor for Retinal Pigment Epithelial Cells under Oxidative Stress via the VEGF-R2/PI3K/AktInvestigative Ophthalmology & Visual Science, 2010
- Efficient identification of tubby‐binding proteins by an improved system of T7 phage displayJournal of Molecular Recognition, 2009
- CCR3 is a target for age-related macular degeneration diagnosis and therapyNature, 2009
- Role of Soluble Vascular Endothelial Growth Factor Receptor-1 in the Vitreous in Proliferative Diabetic RetinopathyOphthalmology, 2008
- Analyzing the “Degree of Humanness” of Antibody SequencesJournal of Molecular Biology, 2007
- Heterozygous embryonic lethality induced by targeted inactivation of the VEGF geneNature, 1996